Cold Chain Technologies is in the process of moving into its new world headquarters in Franklin, a facility that gives the company 100,000 additional square feet for manufacturing and other operations.
Under the advisement of the U.S. Food & Drug Administration, Biostage has decided to extend their animal testing of its Cellframe organ implants and push back its investigational new drug (IND) filing.
Over the past year, Holliston-based Biostage has revamped its upper management, changed its name and used its technology to partially recreate the esophaguses of several Yucatan pigs.
A warehouse in Holliston has sold for $7.2 million to Framingham's Atlantic Importing as the alcohol distributor prepares to move its headquarters as part of an expansion.
Holliston biotechnology firm Biostage has filed for a designation that would allow it to fast-track registrations for its Cellspan esophageal implants and gain a full exemption from the FDA's registration fees.
Biostage is moving closer to human trials of its esophagus regeneration technology, anticipated to take place in 2017, on the back of an additional $5 million in funding gained through a stock offer.